Impact BioMedical Inc.
Price Action
Technical Summary
CONSOLIDATINGImpact BioMedical Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 22), showing significant lag compared to the market leaders. Earnings growth of 79% provides fundamental context to the price action. Investors should exercise caution due to high volatility (109% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.54 | -13.48% | BELOW |
| 50 SMA | $0.58 | -19.13% | BELOW |
| 100 SMA | $0.56 | -15.68% | BELOW |
| 150 SMA | $0.53 | -11.67% | BELOW |
| 200 SMA | $0.55 | -14.30% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IBO in an uptrend right now?
IBO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is IBO overbought or oversold?
IBO's RSI (14) is 37. The stock is in neutral territory, neither overbought nor oversold.
Is IBO outperforming the market?
IBO has a Relative Strength (RS) Rating of 22 out of 99. IBO is currently lagging the broader market.
Where is IBO in its 52-week range?
IBO is trading at $0.47, which is 57% of its 52-week high ($0.83) and 20% above its 52-week low ($0.38).
How volatile is IBO?
IBO has a Beta of -0.49 and 52-week volatility of 109%. It's less volatile than the S&P 500 - generally more stable.